Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

limited therapeutic choices."

The picoplatin data will be presented in a poster session on Friday, February 27, at 11:45 a.m. Eastern Time (abstract #186/poster #A38) during the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary Cancers Symposium in Orlando, Fla. Picoplatin, the Company's lead product candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of solid tumors.

Phase 2 CRPC Trial Design and Results to Date

Patient enrollment in the ongoing Phase 2 trial of picoplatin in patients with metastatic CRPC was completed in December 2007. The trial enrolled 30 patients with metastatic CRPC who had not received prior chemotherapy. The objective of the study is to evaluate the efficacy and safety of intravenous picoplatin (120 mg/m squared) administered every three weeks in combination with full doses of docetaxel (75 mg/m squared) with daily prednisone (5 mg) as a first-line treatment. PSA response (defined as a PSA reduction of at least 50 percent from baseline maintained for at least four weeks) is the primary endpoint; secondary endpoints include safety, radiologic response, time to progression and overall survival.

The latest trial findings, scheduled for presentation at the ASCO 2009 GU Symposium, demonstrated that:

  • Reductions of PSA levels of at least 50 percent were achieved in 21 of 27 (78 percent) evaluable patients who received picoplatin in combination with docetaxel and prednisone. In contrast, data from published literature report PSA responses of approximately 45 percent in patients who received docetaxel/prednisone.
  • To date, the median time to PSA progression is 8.5 months with picoplatin in combination with docetaxel and prednisone.
  • Radiologic response
    '/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Ill. and ST. PAUL, Minn., April ... promote and distribute Abbott,s FreeStyle,Navigator Continuous ... Medical MD is the manufacturer,of the ... and the Deltec Cozmo,insulin pump., ...
... Lorus Therapeutics Inc.,(,Lorus,), a biopharmaceutical company specializing ... and technologies for the management,of cancer, today ... aimed at,expanding the therapeutic application of its ... superficial bladder cancer., The new development ...
... to Tap Alternative Energy Business in China, ... Ltd ("JIC" or "the Company") to be renamed ... a wholly-owned subsidiary of HKC,(Holdings) Limited ("HKC (HOLDINGS) ... in three alternative energy projects at the Lunaobao,Wind ...
Cached Biology Technology:Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System 2Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System 3Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System 4Lorus initiates development program exploring novel route of administration for LOR-2040 2Lorus initiates development program exploring novel route of administration for LOR-2040 3Lorus initiates development program exploring novel route of administration for LOR-2040 4JIC Invests in Three New Alternative Energy Projects 2JIC Invests in Three New Alternative Energy Projects 3JIC Invests in Three New Alternative Energy Projects 4JIC Invests in Three New Alternative Energy Projects 5
(Date:7/30/2014)... colors, nature had already perfected the process think ... example. Now scientists are tapping into those secrets to ... plastics. Their paper on using structure or the ... to produce color appears in the ACS journal ... and colleagues point out that currently, plastic manufacturers add ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2
... techniques, advanced computer simulation and next generation sequencing technology, ... and the Massachusetts Institute of Technology (MIT) have resolved ... chromosomes were first observed under the light microscope by ... that appears in the online edition of Science ...
... known to repair their tissues effortlessly, but can this capacity ... the Stem Cell Program at Boston Children,s Hospital suggests that ... is active in embryonic stem cells, researchers were able to ... tissues in a mouse model. The study also ...
... Bethesda, Md. (Nov. 7, 2013)Obesity has more than doubled ... States in the past 30 years, according to the ... of childhood obesity is a major health concern since ... developing several diseases once considered reserved for adults. These ...
Cached Biology News:UMMS researchers answer century old question about 3D structure of mitotic chromosomes 2UMMS researchers answer century old question about 3D structure of mitotic chromosomes 3UMMS researchers answer century old question about 3D structure of mitotic chromosomes 4Researchers regrow hair, cartilage, bone, soft tissues 2For obese teen girls, aerobic exercise may trump resistance training in health benefits 2For obese teen girls, aerobic exercise may trump resistance training in health benefits 3
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
... The standard of the Axima range, ... high mass accuracy, resolution, sensitivity and ... with both linear and reflectron time-of-flight ... reflectron enables the generation of seamless ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: